1 刘明涛,盛美艳,张芸,等. 环丙沙星联合妥布霉素对兔铜绿假单胞菌环丙沙星耐药突变选择窗的影响[J]. 中华医学杂志,2011, 91(20): 1427~1431. 2 刘洋,徐刚,王敏,等. 酒石酸泰乐菌素联合阿莫西林钠缩小猪链球菌耐药突变选择窗的研究[J]. 中国预防兽医学报,2010, 32(1): 65~67. 3 孙恩华,刘明涛,毕少杰,等. 美罗培南及头孢他啶与其他抗菌药物联合应用对铜绿假单胞菌耐药突变选择窗的研究[J]. 中华医院感染学杂志,2011, 21(4): 631~633. 4 Almeida D, Nuermberger E, Tyagi S, et al. In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis[J]. Antimicrobial Agents and Chemotherapy, 2007, 51(12):4261~4266. 5 Baquero F, Neqri M C. Strategies to minimize the development of antibiotic resistance[J]. Journal of Chemotherapy, 1997, 9(5): 29~37. 6 Blonedau J M, Hansen G, Metzler K, et al. The role of PK/PD parameters to avoid selection and increase of resistance: Mutant prevention concentration[J]. Journal of Chemotherapy, 2004, 16(3): 1~19. 7 Craig W A. Pharmaconamics of antimicrobials: General concepts and applications. In: Nightingale C, Murakawa T, Ambrose P, eds. Antimicrobial pharmacodynamics in theory and clinical practice, New York: Murcel Dekker, 2002. 8 Credito K, Kosowska-Shick K, McGhee P, et al. Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against Pneumococci[J]. Antimicrobial Agents and Chemotherapy, 2009, 54(2):673~677. 9 Croisier D, Etienne M, Piroth L, et al. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: Impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants[J]. Journal of Antimicrobial Chemotherapy, 2004, 54(3):640~647. 10 Cui J C, Liu Y N, Wang R, et al. The mutant selection window in rabbits infected with Staphylococcus aureus[J]. The Journal of Infectious Diseases, 2006, 194(11): 1601~1608. 11 Drlica K, Zhao X. Mutant selection window hypothesis updated[J]. Clinical Infectious Disease, 2007, 44(5):681~688. 12 Drlica K. The mutant selection window and antimicrobial resistance[J]. Journal of Antimicrobial Chemotherapy, 2003, 52(1):11~17. 13 Ferran A A, Kesteman A S, Toutain P L, et al. Pharmacokinetic/pharmacodynamic analysis of the influence of inoculum size on the selection of resistance in Escherichia coli by a Quinolone in a mouse thigh bacterial infection model[J]. Antimicrobial Agents and Chemotherapy, 2009, 53(8): 3384~3390. 14 Firsov A A, Vostrov S N, Lubenko I Y, et al. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus[J]. Antimicrobial Agents and Chemotherapy, 2003, 47(5):1604~1613. 15 Gloede J, Scheerans C, Derendorf H, et al. In vitro pharmacodynamic models to determine the effect of antibacterial drugs[J]. Journal of Antimicrobial Chemotherapy, 2009, 65(2):186~201. 16 Jacobs M R, Felmingham D, Appelbaum P C, et al. The alexander project 1998~2000: Susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents[J]. Journal of Antimicrobial Chemotherapy, 2003, 52(2):229~246. 17 Jumbe N, Louie A, Deziel M R, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy[J]. Journal of Clinical Investigation, 2003, 112(2):275~285. 18 Liang B B, Bai N, Cai Y, et al. Mutant prevention concentration-based pharmacokinetic/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacin-resistant subpopulations of Staphylococcus aureus[J]. Antimicrobial Agents and Chemotherapy, 2011, 55(5):2409~2412. 19 Liu Y, Cui J C, Wang R, et al. Selection of rifampicin-resistant Staphylococcus aureus during tuberculosis therapy: Concurrent bacterial eradication and acquisition of resistance[J]. Journal of Antimicrobial Chemotherapy, 2005, 56(6):1172~1175. 20 Mallk M, Hoatam G, Chavda K, et al. Novel approach for comparing the abilities of quinolones to restrict the emergence of resistant mutants during quinolone exposure[J]. Antimicrobial Agents and Chemotherapy, 2009, 54(1):149~156. 21 Nielsen E I, Cars O, Friberg L E. Pharmacokinetic/Pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: A step toward model-based dose optimization[J]. Antimicrobial Agents and Chemotherapy, 2011, 55(10):4619~4630. 22 Pope C F, O’Sullivan D M, Mchugh T D, et al. A practical guide to measuring mutation rates in antibiotic resistance[J]. Antimicrobial Agents and Chemotherapy, 2008, 52(4):1209~1214. 23 Sindelar G, Zhao X, Liew A, et al. Mutant prevention concentration as a measure of fluoroquinolone potency against Mycobacteria[J]. Antimicrobial Agents and Chemotherapy, 2000, 44(12):3337~3343. 24 Yuan Z, Ledesma K R, Singh R, et al. Quantitative assessment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model[J]. The Journal of Infectious Diseases, 2010, 201(6):889~897. 25 Zhou J F, Dong Y Z, Zhao X L, et al. Selection of antibiotic-resistant bacterial mutants: Allelic diversity among fluoroquinoloue-resistant mutations[J]. The Journal of Infectious Diseases, 2000, 182(8): 517~525. 26 Zinner S H, Lubenko I U, Gilbert D, et al. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: Related changes in susceptibility, resistance frequency and bacterial killing[J]. Journal of Antimicrobial Chemotherapy, 2003, 52(4):616~622. |